Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-010 + gp100 Peptides + Montanide ISA 51 in Stage IV Melanoma
NCT00032045Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by National Cancer Institute. Started Jan 2002; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00032045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00032045.